SOURCE: BioTech Medics, Inc.

November 29, 2007 10:28 ET

BioTech Medics, Inc. Closes With Nutricutical Company

DALLAS, TX--(Marketwire - November 29, 2007) - BioTech Medics, Inc. (PINKSHEETS: BMCS) announced that it has closed on the acquisition of BioBody Product formula, trademarks and copyrights.

Keith Houser, CEO, stated: "As a part of our pledge to increase the value of BMCS, BioTech Medic's Wellness program, we want to offer some of the best proprietary nutricutical health products available to the public. BioBody has four proven products which complement our goals and objectives of wellness. BioBody also brings the expertise and knowledge to help BMCS to expand Internet sales and marketing of BioTech's exclusive and patented SHBAN™ products."

BioBody is an eight year old Texas company with over $5 million in gross sales that offers proprietary ingredient patented products which help the body to function at its best. The main line product is BioBody Balance™ a liquid multivitamin supplement. BioBody Products are featured on the web at

BioTech Medics is a distributor of the high powered NeuroLase™ Therapeutic Medical Laser. The high powered medical laser provides relief from muscular, skeletal and arthritic pain. BMCS operates a Pain Management & Wellness Center in Dallas with Charles R. Crane, MD. BMCS plans on closing on more new Pain Management & Wellness Centers in 2008. Affiliated pain centers are also in Overland Park, Kansas, Albuquerque, New Mexico and Los Angeles.

BioTech intends to strive to add more assets and increased revenue for the company in 2008 to bring more value to the stock.

Safe Harbor for Forward-Looking Statements

This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 (the "Act"). The words "plan," or "intend to," and similar conditional expressions are intended to identify forward-looking statements within the meaning of the Act and are subject to the safe harbor created by the Act. Such statements are subject to certain risks and uncertainties and actual results could differ materially from those expressed in any of the forward-looking statements. Such risks and uncertainties include, but are not limited to, the ability of the company to have adequate financing, market conditions, the general acceptance of the Company's products and technologies, competitive factors, timing, and other risks described in various Company publications. The FDA has not evaluated BioBody nor SHBAN. BioBody and SHBAN is not to be used to diagnose, cure or treat any disease.

Contact Information